Skin metastases from transitional cell carcinoma are quite rare. The present case report describes the results of a combination of mitomycin C and lonidamine administered as third-line chemotherapy in a patient with pulmonary and skin involvement from bladder cancer. The partial response obtained suggests that further testing should be carried out on the activity of this association in a second-line approach.
Get full access to this article
View all access options for this article.
References
1.
BoccardoF., GuarnieriD., PaceM., DecensiA., OnetoF., MartoranaG.: Phase II study with LND in the treatment of hormone-refractory prostatic cancer patients. Tumori:78: 137–139, 1992.
2.
CrawfordE.D., SaiersJ.H., BakerL.H., CostanziJ.H., BukowskiR.M.: Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group Study. Urology, 38: 355–357, 1991.
3.
DirixL.C., Van OosteromA.T.: Neoadjuvant and adjuvant therapy for invasive bladder tumors. Eur. J. Cancer, 27: 326–330, 1992.
4.
DogliottiL., BerrutiA., BunivaT., ZolaP., BauM.G., FarrisA., SarobbaM.G., BottiniA., AlquatiP., DeltettoF., GossoP., MonzeglioC., MoroG., SussioM., PerroniM.: High-dose epirubicin vs. high-dose epirubicin plus lonidamine in advanced breast cancer: a multicenter randomized trial (Abst.). Proc. Am. Soc. Clin. Oncol., 13: 58, 1994.
5.
GetzmeierU., CavalliF., HaussingerK., KaukelE., KoschelG., MartinalliG., NeuhaussR., von PawelJ.: Phase III trial with and without lonidamine in NSCLC. Semin. Oncol., 18: 42–48, 1991.
6.
HamdyF.C., HastieK.J., KerryR., WilliamsJ.J.: Mitomycin C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment? Br. J. Urol., 71: 183–186, 1993.
7.
LopezM., CarpanoS., D'AprileM., ViciP., GionfraT., SacchiI., PignattiF., Di FilippoF., Del MedicoP., Di LauroL.: High-dose epirubicine ± lonidamine in adult patients with advanced sarcomas (Abst.). Proc. Am. Soc. Clin. Oncol., 11: 414, 1992.
8.
Robustelli della CunaG., PedrazzoliP.: Toxicity and clinical tolerance of lonidamine. Semin. Oncol., 18: 18–22, 1991.
9.
SilvestriniR., ZaffaroniM., VillaR., OrlandiL., CostaA.: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int. J. Cancer, 52: 813–817, 1992.
StahlM., SchmollE., BeckerH., SchlichterA., HoffmannL., WagnerH., PossingerK., MullerW., KollermannM., WeidennhammerW., SchmollH.J.: Lonidamine versus high-dose tamoxifen in progressive advanced renal cell carcinoma: results of an ongoing randomized phase II study. Semin. Oncol., 18: 33–37, 1991.
12.
VeronesiA., Lo ReG., TumoloS., MorassutS., BelmonteP., FranciniM., MonfardiniS.: Partial response to lonidamine of advanced bladder carcinoma: a case report. Tumori, 76: 290–291, 1990.
13.
WamanJ.: Chemotherapy for metastatic bladder cancer. Is there new hope? Br. J. Urol., 65: 1–5, 1990.
14.
ZaffaroniN., BearzattoA., GornatiD., SilvestriniR.: Effect of lonidamine on the cytotoxic activity of cisplatin, mitomycin C and BCNU in human ovarian and colon carcinoma cells. Int. J. Oncol., 4: 773–778, 1994.
